Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01UHA
|
|||
| Former ID |
DIB012100
|
|||
| Drug Name |
MIS-416
|
|||
| Synonyms |
Microparticle adjuvant (anthrax), Virionyx; Microparticle adjuvant (iv, autoimmune disease/cancer/anthrax), Innate Therapeutics
Click to Show/Hide
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 2 | [1] | |
| Bacillus anthracis infection [ICD-11: 1G40] | Investigative | [1] | ||
| Company |
Innate Therapeutics Ltd
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis. PLoS ONE 9(1): e87712. January 31, 2014. | |||
| REF 2 | DOI: 10.1371/journal.pone.0087712 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.